Drug Manufacturers

Making the Most of Your Scale Down Model

By Fujifilm Diosynth Biotechnologies

In 2002 the US Food and Drug Administration began its initiative to modernise the regulation of pharmaceutical manufacturing and product quality and initiated the concept of Quality by Design (QbD) for pharmaceuticals. QbD principles and advice for implementation are outlined in regulatory guidances such as ICH Q8, Q9 and Q10. One of the foundations of QbD, underpinning its operation is that products and processes are sufficiently understood so that those elements most critical for product quality can be identified, codified and controlled.

Download this free white paper to find out more.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.